Bionexus Gene LabBGLC
13F holders, Q1 2025 (March 31)4holders −2
2new positions
4sold out
1famous investor
$0.24avg. 13F price*
At the end of Q1 2025, 4 institutions reported holding Bionexus Gene Lab Corp. (BGLC) in their 13F filings, down 2 from Q4 2024. 2 opened new positions and 4 sold out. The largest holders were Citadel Advisors ($23K), Two Sigma Investments, LP ($8K) and Geode Capital Management, LLC ($6K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Bionexus Gene Lab Corp.
- CUSIP
- 090628207
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $32K |
| Exits | 4 | $13K |
All 13F filers, Q4 2024 → Q1 2025: 134,300 shares bought and 154,412 shares sold, net −20,112 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Citadel Advisors | 0.00% | New | 98,768 | $23K |
| Two Sigma Investments, LP | 0.00% | New | 35,532 | $8K |
| Geode Capital Management, LLC | 0.00% | No change | 23,681 | $6K |
| UBS Group AG | 0.00% | Reduce -100.0% | 4 | $1 |
"% of holder's portfolio" is BGLC's weight in each manager's 13F, not the share of Bionexus Gene Lab Corp. the manager owns.